From One to Many
We need 500 people to donate or share their story for the ABTA’s first Day of Giving during Brain Tumor Awareness Month. Are you in?
GBM Awareness Day is July 17. Join us in raising awareness all month long! Learn more.
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
We need 500 people to donate or share their story for the ABTA’s first Day of Giving during Brain Tumor Awareness Month. Are you in?
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Featured Clinical Study A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02) Study Sponsor:
Featured Clinical Study A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER) Study Sponsor: Boston Scientific Study website: Frontier Study
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study).
Meet two researchers on opposite ends of the globe dedicated to transforming the future of brain tumor treatments.
Read our top takeaways from the Society for Neuro-Oncology (SNO) Annual Meeting, the world’s largest gathering of neuro-oncology experts.
Always free for patients & caregivers
Gina & Tim Abbas
Caregiver & Anaplastic Astrocytoma Survivor
Donate now and your gift will be matched thanks to the Will Hicks Charitable Association.
